Metropolis Healthcare Ltd. (METROPOLIS) AI Stock Analysis

• Market Cap: ₹100.63B
• Dividend Yield: 0.71%
• Average Volume (3M): 3.90K
• Price to Earnings (P/E): 65.8
• Beta (1Y): 0.70
• Revenue Growth: 12.86%
• EPS Growth: 10.42%
• Country: IN
• Employees: 4,313
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 8.80
• Shares Outstanding: 51,807,460
• 10 Day Avg. Volume: 4,604
• 30 Day Avg. Volume: 3,901
• PEG Ratio: 4.05
• Price to Book (P/B): 5.90
• Price to Sales (P/S): 5.90
• P/FCF Ratio: 35.81
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹2,249.50
• Price Target Upside: 15.82% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 61 Neutral
• Price Target: ₹2,099.00 ▲(8.07% Upside)

Metropolis Healthcare Ltd. has a strong financial foundation, which is the most significant factor in its overall score. However, technical analysis indicates potential short-term weakness, and the high P/E ratio suggests overvaluation, which detracts from the stock's attractiveness. The absence of earnings call data and corporate events means these factors do not influence the score.

Metropolis Healthcare Ltd. Business Overview & Revenue Model

Company Description

Metropolis Healthcare Limited provides diagnostic services in India. It offers clinical laboratory testing, and profiles and support services. The company provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as various health check-up packages for men, women, senior citizens, and youth and corporates. Its tests and profiles are used for prediction, early detection, diagnostic screening, confirmation, and/or monitoring of the disease. The company also offers corporate wellness and hospital laboratory solutions, as well as clinical research services. As of March 31, 2022, it operated 171 clinical laboratories, 9,000 pick-up points, and 704 assisted referral centers. The company was founded in 1980 and is headquartered in Mumbai, India.

How the Company Makes Money

Metropolis Healthcare Ltd. generates revenue primarily through its extensive network of diagnostic laboratories and patient service centers. The company's main revenue streams include fees charged for various clinical laboratory tests and pathology services. These tests cover a broad spectrum, from routine blood tests and imaging to specialized diagnostics, catering to both walk-in patients and institutional clients such as hospitals and clinics. Additional revenue is derived from preventive healthcare packages and wellness programs aimed at promoting early detection and prevention of diseases. Furthermore, Metropolis may engage in partnerships with healthcare providers, insurance companies, and corporate clients to offer customized health check-up plans, which contribute to its earnings. The company invests in technological advancements and quality assurance to maintain its competitive edge and ensure customer satisfaction, which is crucial for sustaining its revenue growth.

Metropolis Healthcare Ltd. Financial Statement Overview

Summary

Metropolis Healthcare Ltd. exhibits strong financial health across all verticals. The income statement reflects robust revenue and profit growth, indicating competitive strength and operational efficiency. The balance sheet is solid with low leverage and a strong equity base, reducing financial risk. The cash flow statement underscores efficient cash conversion and growth, supporting expansion and shareholder value. The company is well-positioned for sustainable growth in the Medical - Diagnostics & Research industry.

Income Statement

Metropolis Healthcare Ltd. shows strong performance with a consistent increase in revenue and profitability. The gross profit margin is impressive at 79.8% for 2025, indicating effective cost management. The net profit margin has also improved, reaching 10.9% in 2025, reflecting enhanced operational efficiency. EBIT and EBITDA margins stand at 55.5% and 22.8% respectively, demonstrating robust profitability. Revenue growth of 10.2% from 2024 to 2025 further underscores the company's solid market position and growth potential.

Balance Sheet

The balance sheet of Metropolis Healthcare Ltd. is strong, supported by a healthy equity ratio of 71.3% in 2025, indicating a solid capital structure. The debt-to-equity ratio is manageable at 0.15, reflecting low leverage and thus reduced financial risk. Return on equity is 10.9%, highlighting efficient use of shareholder funds. Overall, the company maintains a stable and low-risk financial position, which provides a strong foundation for future growth.

Cash Flow

Cash flow generation is robust, with a free cash flow growth rate of 9.5% from 2024 to 2025, indicating efficient operations and sound financial health. The operating cash flow to net income ratio is strong at 1.81, showing that the company generates ample cash relative to its profitability. Free cash flow to net income ratio is high at 1.51, demonstrating a solid ability to convert profits into cash. Overall, Metropolis Healthcare Ltd. showcases a strong cash flow profile, facilitating business expansion and shareholder returns.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	14.04B	13.31B	12.08B	11.48B	12.28B	9.98B
Gross Profit	12.14B	10.63B	5.36B	8.88B	9.41B	7.38B
EBITDA	3.26B	3.03B	2.97B	3.08B	3.81B	3.01B
Net Income	1.52B	1.45B	1.28B	1.43B	2.14B	1.83B
Balance Sheet
Total Assets	0.00	18.67B	15.55B	15.02B	15.30B	10.04B
Cash, Cash Equivalents and Short-Term Investments	1.18B	1.18B	1.24B	1.20B	1.81B	4.20B
Total Debt	0.00	2.04B	1.97B	2.66B	3.79B	1.12B
Total Liabilities	-13.35B	5.33B	4.56B	5.11B	6.42B	2.96B
Stockholders Equity	13.35B	13.31B	10.96B	9.88B	8.86B	7.07B
Cash Flow
Free Cash Flow	0.00	2.19B	2.00B	1.94B	2.23B	2.21B
Operating Cash Flow	0.00	2.63B	2.64B	2.47B	2.53B	2.49B
Investing Cash Flow	0.00	-2.01B	-894.12M	467.94M	-7.38B	617.01M
Financing Cash Flow	0.00	-866.34M	-1.81B	-2.92B	1.63B	-326.90M

Metropolis Healthcare Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1942.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:METROPOLIS, the sentiment is Negative. The current price of 1942.3 is below the 20-day moving average (MA) of 2021.61, below the 50-day MA of 2084.02, and above the 200-day MA of 1836.23, indicating a neutral trend. The MACD of -36.38 indicates Positive momentum. The RSI at 39.14 is Neutral, neither overbought nor oversold. The STOCH value of 4.97 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:METROPOLIS.

Metropolis Healthcare Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
THYROCARE	69 Neutral	₹65.94B	51.62	―	1.69%	22.36%	52.01%
VIJAYA	67 Neutral	₹102.99B	68.56	―	0.20%	22.34%	20.71%
LALPATHLAB	66 Neutral	₹264.53B	51.28	―	0.77%	10.57%	34.11%
KRSNAA	62 Neutral	₹26.45B	32.84	―	0.33%	13.78%	32.21%
HCG	61 Neutral	₹99.96B	275.51	―	―	16.85%	-29.57%
METROPOLIS	61 Neutral	₹100.63B	65.79	―	0.71%	12.86%	10.42%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%